---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-009139"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:53:38.593995+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia doses first patient in 48 mg MAD cohort of Phase 1 obesity trial; Q4 top-line data expected

## Summary
- First patient dosed in 48 mg multiple ascending dose cohort of DA-1726 (GLP1R/GCGR dual agonist) for obesity.
- Prior 32 mg data: mean weight loss 4.3%, max 6.3% at Day 26 (p=0.0005); 83% early satiety; average waist reduction 1.6 inches by Day 33.
- Fasting glucose reduced up to 18 mg/dL without hypoglycemia; no QTcF prolongation; mild GI side effects, suggesting favorable tolerability.
- CEO stated DA-1726 has best-in-class potential with no titration needed; top-line results from 48 mg cohort expected Q4 2025.

## SEC filing metadata
- accession: 0001558370-25-009139
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025009139/0001558370-25-009139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025009139/mtva-20250709x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-009139
- JSON: https://secwatch.observer/filing/0001558370-25-009139.json
- Plain text: https://secwatch.observer/filing/0001558370-25-009139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.